EP Patent

EP2214650A2 — Bupropion hydrobromide and therapeutic applications

Assigned to Valeant International Bermuda · Expires 2010-08-11 · 16y expired

What this patent protects

Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.

USPTO Abstract

Bupropion hydrobromide formulations as well as their use for the treatment of conditions is described.

Drugs covered by this patent

bupropion-hydrobromide (BUPROPION HYDROBROMIDE)

Patent Metadata

Patent number: EP2214650A2
Jurisdiction: EP
Classification: —
Expires: 2010-08-11
Drug substance claim: No
Drug product claim: No
Assignee: Valeant International Bermuda
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.